发布求助
文献互助 智能选刊 最新文献

Skinmed最新文献

筛选
英文 中文
Idiopathic Granulomatous Mastitis Associated with Erythema Nodosum in a Pregnant Woman. 一名孕妇伴有结节性红斑的特发性肉芽肿性乳腺炎
Skinmed Pub Date : 2023-12-05 eCollection Date: 2023-01-01
Anissa Zaouak, Chamli Amal, Raboudi Asma, Fatma Daoud, Ehsen Ben Brahim, Houda Hammami, Samy Fenniche
{"title":"Idiopathic Granulomatous Mastitis Associated with Erythema Nodosum in a Pregnant Woman.","authors":"Anissa Zaouak, Chamli Amal, Raboudi Asma, Fatma Daoud, Ehsen Ben Brahim, Houda Hammami, Samy Fenniche","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 32-year-old woman at 17 weeks' gestation presented with fever and a 1-week history of an acute nodular eruption involving her legs, along with bilateral ankle and knee pain. She also had had a recurrent right breast abscess for 2 months for which she had been treated with oral antibiotics and surgical drainage, but with slight improvement. Cultures of the abscess showed no bacteria or fungi. She had no history of tuberculosis, sarcoidosis, trauma to the breast, or a family history of breast pathology. Cutaneous examination revealed multiple, tender, erythematous, subcutaneous nodules on her legs (Figure 1) and an ill-defined tender mass involving the inferior quadrant of the right breast without nipple discharge or retraction. There was a scar with drainage on her right breast (Figure 2). There were no regional lymphadenopathies. Left breast and left axilla examination was unremarkable. Significant laboratory findings included an erythrocyte sedimentation rate of 54 mm/hour (normal levels [NL] < 20 mm/hour), an elevated C reactive protein at 148 mg/L (NL < 5 mg/L), and a high level of white blood cells averaging 15,000 elements/mm<sup>3</sup> (NL < 10,000/mm<sup>3</sup>).</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138489452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Longitudinal Surface Ridges on the Nail Plate. 甲板上的纵向表面皱纹
Skinmed Pub Date : 2023-12-05 eCollection Date: 2023-01-01
Nardo Zaias, Sandra X Escovar, Natalie G Dou, Martin N Zaiac, Carlos Ricotti, Agnese Canazza
{"title":"Longitudinal Surface Ridges on the Nail Plate.","authors":"Nardo Zaias, Sandra X Escovar, Natalie G Dou, Martin N Zaiac, Carlos Ricotti, Agnese Canazza","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138489456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perception of Patients Attending Dermatology Outpatient Services during the COVID-19 Pandemic. COVID-19 大流行期间皮肤科门诊患者的看法。
Skinmed Pub Date : 2023-12-05 eCollection Date: 2023-01-01
James Ralph, Jennifer Boggs, Ciara O'Grady, Benvon Moran
{"title":"Perception of Patients Attending Dermatology Outpatient Services during the COVID-19 Pandemic.","authors":"James Ralph, Jennifer Boggs, Ciara O'Grady, Benvon Moran","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138489460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coexistence of Ichthyosis, Yellowish Keratoderma, and Neurologic Manifestations: Think About Sjogren-Larsson Syndrome. 鱼鳞病、淡黄色角化病和神经系统表现并存：想想 Sjogren-Larsson 综合征。
Skinmed Pub Date : 2023-12-05 eCollection Date: 2023-01-01
Anissa Zaouak, Ghaith Abdessalem, Amal Chamli, Olfa Messoud, Mediha Trabelsi, Samy Fenniche, Sonia Abdelhak, Houda Hammami
{"title":"Coexistence of Ichthyosis, Yellowish Keratoderma, and Neurologic Manifestations: Think About Sjogren-Larsson Syndrome.","authors":"Anissa Zaouak, Ghaith Abdessalem, Amal Chamli, Olfa Messoud, Mediha Trabelsi, Samy Fenniche, Sonia Abdelhak, Houda Hammami","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138489432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dermatology: Visual Recognition and Case Reviews. 皮肤病学视觉识别和病例回顾。
Skinmed Pub Date : 2023-12-05 eCollection Date: 2023-01-01
Alina Shevchenko
{"title":"Dermatology: Visual Recognition and Case Reviews.","authors":"Alina Shevchenko","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138489434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LITFULOTM (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata. LITFULOTM（瑞替尼）胶囊：用于治疗严重脱发的 Janus 激酶 3 抑制剂。
Skinmed Pub Date : 2023-12-05 eCollection Date: 2023-01-01
Aditya K Gupta, Shruthi Polla Ravi, Kimberly Vincent, William Abramovits
{"title":"LITFULO<sup>TM</sup> (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata.","authors":"Aditya K Gupta, Shruthi Polla Ravi, Kimberly Vincent, William Abramovits","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>LITFULO<sup>TM</sup> (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome, Severity of Alopecia Tool (SALT) score of ≤20, at week 24 (31% [38/124] 200-mg ritlecitinib QD for 4 weeks, then 50 mg QD for 20 weeks; 22% [27/121] 200-mg ritlecitinib QD for 4 weeks, then 30 mg QD for 20 weeks; 23% [29/124] 50-mg ritlecitinib QD; 14% [17/119] 30-mg ritlecitinib QD; 2% [1/59] 10-mg ritlecitinib QD; and 2% [2/130] placebo). Mild to moderate common adverse effects were observed, which included headache, nasopharyngitis, and upper respiratory tract infection. The recommended regimen of ritlecitinib capsules is 50 mg QD with without food and swallowed whole.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138489454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Little Blue Dot Disease: A Critical Dermatopathologic Difference of Diagnosis. 小蓝点病：关键的皮肤病理学诊断差异。
Skinmed Pub Date : 2023-12-05 eCollection Date: 2023-01-01
Karl Hoegler, Douglas H Atmatzidis, Amy Weiss, Rajendra Kapila, W Clark Lambert
{"title":"Little Blue Dot Disease: A Critical Dermatopathologic Difference of Diagnosis.","authors":"Karl Hoegler, Douglas H Atmatzidis, Amy Weiss, Rajendra Kapila, W Clark Lambert","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138489455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ketogenic Diet and the Skin. 生酮饮食与皮肤。
Skinmed Pub Date : 2023-11-10 eCollection Date: 2023-01-01
Dana Harb, Lina Abdullah, Mazen Kurban, Ossama Abbas
{"title":"Ketogenic Diet and the Skin.","authors":"Dana Harb, Lina Abdullah, Mazen Kurban, Ossama Abbas","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In dermatology, the role of dietary modifications as a means to manage or prevent skin disorders has recently gained special attention among patients and physicians. This is especially true for the currently popular ketogenic diet (KD), which comprises low carbohydrate, high fat, and adequate amount of protein. Recent evidence from basic science research, small clinical trials, population studies, and reports has presented promising potential role of KD as a supplementary or adjuvant treatment in different cutaneous disorders mainly due to its anti-inflammatory properties. This review is directed at raising awareness among dermatologists on the potential uses of KD in managing skin disorders, such as acne, psoriasis, and hidradenitis suppurativa, among others. In addition, cutaneous adverse reactions, such as prurigo pigmentosa and nutritional deficiencies, which have been associated with KD, are also discussed in this review.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72016618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
YCANTHTM (Cantharidin) Topical Solution. YCANTHTM（Cantharidin）局部溶液。
Skinmed Pub Date : 2023-11-10 eCollection Date: 2023-01-01
Aditya K Gupta, Avantika Mann, Kimberly Vincent, William Abramovits
{"title":"YCANTH<sup>TM</sup> (Cantharidin) Topical Solution.","authors":"Aditya K Gupta, Avantika Mann, Kimberly Vincent, William Abramovits","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>YCANTH<sup>TM</sup> (cantharidin) topical solution has been approved recently for the treatment of molluscum contagiosum (MC) in children (aged ≥2 years) and adults. It works by activating serine proteases that lead to blistering and inflammation, promoting shedding of infected cells and viral clearance. In two phase-3, randomized, double-blind, vehicle-controlled trials of similar design, VP-102 (a drug-device combination, containing cantharidin 0.7% w/v and inactive ingredients, such as gentian violet, acetone, and denatonium benzoate, administered with an applicator) was investigated for the treatment of MC. VP-102 and vehicle were applied topically once every 21 days until complete clearance of lesions was observed, or for up to four treatments. Cantharidin demonstrated efficacy in achieving the primary outcome, at day 84/visit 4 (Cantharidin Application in Molluscum Patients [CAMP-1], VP-102: 46% [73/160], vehicle: 18% [19/106]; and CAMP-2, VP-102: 54% [81/150], vehicle: 13% [15/112]). Common adverse events were mild to moderate, such as lesions at the site of application, pruritus, and pain. The recommended regimen of cantharidin topical solution is its application once every 21 days until complete clearance of lesions is observed, or up to four treatments.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72016629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ZORYVETM (Roflumilast) Cream: A Topical Phosphodiesterase-4 Inhibitor for the Treatment of Psoriasis. ZORYVETM（罗氟司特）乳膏：一种治疗银屑病的局部磷酸二酯酶-4抑制剂。
Skinmed Pub Date : 2023-11-10 eCollection Date: 2023-01-01
Aditya K Gupta, Shruthi Polla Ravi, Kimberly Vincent, William Abramovits
{"title":"ZORYVE<sup>TM</sup> (Roflumilast) Cream: A Topical Phosphodiesterase-4 Inhibitor for the Treatment of Psoriasis.","authors":"Aditya K Gupta, Shruthi Polla Ravi, Kimberly Vincent, William Abramovits","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>ZORYVE<sup>TM</sup> (roflumilast) cream is a topical phosphodiesterase-4 (PDE-4) inhibitor that has been recently approved for the treatment of plaque psoriasis. It is also indicated for use in intertriginous areas. Roflumilast, the active ingredient, inhibits PDE-4, leading to the suppression of pro-inflammatory immune responses in psoriatic lesions. Two phase 3 clinical trials have demonstrated the efficacy of once daily application of roflumilast to treat plaque psoriasis in patients aged 12 years and older. At week 8, an investigator's global assessment score of 0 or 1 with a grade 2 improvement from baseline, the primary efficacy end point, was observed in 39.1% (225/576) of patients applying roflumilast, compared to 6.6% (20/305) of patients applying vehicle. Common adverse events reported were diarrhea, headache, insomnia, nausea, pain at application site, upper respiratory tract infection, and urinary tract infection.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72016630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信